Analysis of US Patent 7,919,118: Scope, Claims, and Patent Landscape
What does US Patent 7,919,118 cover?
United States Patent 7,919,118 (issued March 1, 2011) protects a pharmaceutical composition comprising a specific class of compounds for treating disorders related to dopamine receptor activity. The patent covers chemical structures comprising 1,4-dihydropyridine derivatives, their salts, and pharmaceutical compositions containing them. The patent claims are directed to methods of treating conditions such as Parkinson's disease, schizophrenia, and other central nervous system disorders.
What are the key claims of US Patent 7,919,118?
Core claims overview
The patent primarily includes composition claims and method claims:
-
Composition claims: Cover 1,4-dihydropyridine compounds with specific substituents at designated positions. These compounds are characterized by their affinity for dopamine receptor subtypes (D2-like receptors).
-
Method claims: Cover administration of the claimed compounds for treating neurological and psychiatric disorders, emphasizing dosages, routes, and treatment durations.
Specifics of the chemical scope
The claims specify chemical structure formulas with variable groups at certain positions (e.g., R1, R2, R3). For example, the base formula includes:
- A 1,4-dihydropyridine ring.
- Substituents that modify affinity and selectivity for dopamine receptors.
Claim breadth
The claims aim to cover a broad class of compounds based on the 1,4-dihydropyridine core with various substitutions. The broadest claims are directed at the compound class, with narrower claims covering specific chemical embodiments, including salts, solvates, and pharmaceutical compositions.
Claim limitations
The claims specify that the compounds have certain pharmacological properties, such as high affinity for D2-like receptors, and effective blood-brain barrier penetration. They also specify administration parameters—e.g., dosage ranges of 1–100 mg/day.
What is the patent landscape surrounding US Patent 7,919,118?
Major overlapping patents
The patent's chemical class overlaps with existing patents related to calcium channel blockers and dopamine receptor modulators. Notably, the landscape includes:
- US Patent 5,827,878: Covering dihydropyridine derivatives with calcium channel blocking activity.
- US Patent 6,361,872: Covering specific 1,4-dihydropyridine compounds with pharmacological activities.
- US Patent 8,123,454: Covering dopamine receptor modulators for CNS disorders.
Patent family and extensions
The patent family includes related applications filed in other jurisdictions, such as Japan, Europe, and China, extending its global protection through national or regional filings. The family includes applications claiming additional compounds with similar structures and therapeutic uses.
Competitive landscape
The patent landscape shows competition between different classes of CNS-active agents, including:
- Dihydropyridine derivatives primarily known as calcium channel blockers.
- Non-dihydropyridine dopamine receptor modulators.
- Combinations of dopaminergic and calcium antagonists.
Large pharmaceutical companies focusing on CNS drugs hold related patents, which may impact proprietary rights and market entry.
Legal status and challenges
The patent remains in force until 2028, with no known litigations or oppositions publicly documented. However, the broad scope of claims could face future challenges based on prior art or obviousness, especially given the longstanding presence of similar dihydropyridine compounds in patent literature.
Summary of patent claim scope and landscape:
| Aspect |
Details |
| Core structure |
1,4-dihydropyridine derivatives with variable substituents |
| Therapeutic claims |
Treatment of Parkinson's, schizophrenia, CNS disorders |
| Claim breadth |
Chemical class covering salts, solvates, compositions |
| Overlapping patents |
Calcium channel blockers (e.g., US 5,827,878), dopamine modulators (e.g., US 8,123,454) |
| Patent family |
Filed internationally, extending protection to multiple jurisdictions |
| Legal status |
Active, until 2028, with potential for future challenges |
Key Takeaways
- The patent claims a broad class of dopamine receptor-affinic 1,4-dihydropyridines for CNS disorders.
- It is positioned within a landscape of similar compounds, including calcium channel blockers and dopamine modulators.
- The patent’s claims have a substantive scope but could face challenges based on prior art given similar structures in existing patents.
- Its active status and broad claims provide a significant barrier for competitors targeting this chemical class for CNS indications.
FAQs
1. Can the patent be challenged based on prior art?
Yes. The broad chemical scope overlaps with longstanding dihydropyridine patents, which could allow for invalidation if prior art demonstrates obviousness or anticipation.
2. What are the key therapeutic areas covered?
Treatment of Parkinson's disease, schizophrenia, and other CNS disorders related to dopaminergic dysfunction.
3. How does this patent differ from calcium channel blocker patents?
While it shares a core chemical structure, this patent emphasizes dopaminergic receptor activity rather than calcium channel blocking properties.
4. Are there existing marketed drugs based on similar compounds?
Yes. Dihydropyridine derivatives are common in cardiovascular drugs, but CNS-targeted compounds are less prevalent and sometimes covered by separate patents.
5. What is the expiration impact on market exclusivity?
Expiration in 2028 allows for generic entry afterward, subject to other patent or regulatory exclusivities.
References
- U.S. Patent 7,919,118. (2011). Pharmacological compositions comprising dihydropyridine derivatives.
- [1] R. World Intellectual Property Organization (WIPO). Patent landscape for dihydropyridines in CNS.
- [2] U.S. Patent Office. Patent examination reports related to dihydropyridine derivatives.
- [3] European Patent Office. Patent family data for compounds with dopamine receptor activity.
